PHARMACOKINETICS OF PIPERACILLIN IN PATIENTS ON PERITONEAL-DIALYSIS WITH AND WITHOUT PERITONITIS

被引:9
作者
DEBRUYNE, D [1 ]
RYCKELYNCK, JP [1 ]
DELIGNY, BH [1 ]
MOULIN, M [1 ]
机构
[1] UNIV HOSP CTR CAEN,DIV NEPHROL,F-14000 CAEN,FRANCE
关键词
D O I
10.1002/jps.2600790204
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The pharmacokinetics of piperacillin given intravenously (1 or 2 g) to nine patients with chronic renal failure and undergoing continuous ambulatory peritoneal dialysis was intermediate between values obtained in healthy volunteers and in patients with renal insufficiency studied between dialyses: half‐life, 2.4 h; total clearance, 100 mL/min; urinary or peritoneal clearance, 3 mL/min. The intraperitoneal administration of piperacillin in dialysis fluid (400 mg or 1 g to five patients) increased the half‐life (6 to 7 h) and decreased the volume of distribution of about two thirds. In both instances, the area under the curve was well correlated with dosage. The absorption of piperacillin by an inflamed peritoneum in eight patients suffering from peritonitis and treated with 400 mg, 1 g, or 2 g, was increased and returned to normal concurrently with care. Consequently, the recommended dosage is intravenous administration of 2 g of piperacillin every 8 h or intraperitoneal administration of 1 g every 6 h in the dialysate. With such conditions, serum concentrations greater than minimal inhibitory concentrations and sufficient to avoid dissemination of piperacillin‐susceptible organisms without risk of accumulation are obtained. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company
引用
收藏
页码:99 / 102
页数:4
相关论文
共 12 条
[1]   THE EFFECT OF PIPERACILLIN DOSE ON ELIMINATION KINETICS IN RENAL IMPAIRMENT [J].
ARONOFF, GR ;
SLOAN, RS ;
BRIER, ME ;
LUFT, FC .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 24 (04) :543-547
[2]  
BATRA VK, 1979, CLIN PHARMACOL THER, V26, P41
[3]   MOXALACTAM AND PIPERACILLIN - A STUDY OF INVITRO CHARACTERISTICS AND PHARMACOKINETICS IN CANCER-PATIENTS [J].
DRUSANO, GL ;
DEJONGH, C ;
NEWMAN, K ;
JOSHI, J ;
WHARTON, R ;
MOODY, MR ;
SCHIMPFF, SC .
INFECTION, 1985, 13 (01) :20-26
[4]  
FU FP, 1978, ANTIMICROB AGENTS CH, V13, P358
[5]  
LAU A, 1985, INT J CLIN PHARM TH, V28, P391
[6]   CLINICAL-EVALUATION OF THE THERAPEUTIC EFFICACY AND TOLERABILITY OF PIPERACILLIN [J].
LUTZ, B ;
MOGABGAB, W ;
HOLMES, B ;
POLLOCK, B ;
BEVILLE, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1982, 22 (01) :10-14
[7]   INVITRO ACTIVITY OF PIPERACILLIN COMPARED WITH THAT OF CARBENICILLIN, TICARCILLIN, AMPICILLIN, CEPHALOTHIN, AND CEFAMANDOLE AGAINST PSEUDOMONAS-AERUGINOSA AND ENTEROBACTERIACEAE [J].
SHAH, PP ;
BRIEDIS, DJ ;
ROBSON, HG ;
CONTERATO, JP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1979, 15 (03) :346-350
[8]  
THOMPSON MIB, 1981, ANTIMICROB AGENTS CH, V13, P944
[9]   PIPERACILLIN - HUMAN PHARMACOKINETICS AFTER INTRAVENOUS AND INTRAMUSCULAR ADMINISTRATION [J].
TJANDRAMAGA, TB ;
MULLIE, A ;
VERBESSELT, R ;
DESCHEPPER, PJ ;
VERBIST, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1978, 14 (06) :829-837
[10]  
TOSOLINI FA, 1985, CURR THER RES CLIN E, V37, P9